These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38892797)

  • 21. Remote care through telehealth for people with inflammatory bowel disease.
    Gordon M; Sinopoulou V; Lakunina S; Gjuladin-Hellon T; Bracewell K; Akobeng AK
    Cochrane Database Syst Rev; 2023 May; 5(5):CD014821. PubMed ID: 37140025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RELATIONSHIP AMONG PSYCHOLOGICAL WELL-BEING, RESILIENCE AND COPING WITH SOCIAL AND CLINICAL FEATURES IN CROHN'S DISEASE PATIENTS.
    Acciari AS; Leal RF; Coy CSR; Dias CC; Ayrizono MLS
    Arq Gastroenterol; 2019 Aug; 56(2):131-140. PubMed ID: 31460575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibiotic use in Crohn's disease: why and how?
    Prantera C; Scribano ML; Berto E; Zannoni F
    BioDrugs; 1997 Oct; 8(4):293-306. PubMed ID: 18020520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The natural history of esophageal Crohn's disease: three patterns of evolution.
    D'Haens G; Rutgeerts P; Geboes K; Vantrappen G
    Gastrointest Endosc; 1994; 40(3):296-300. PubMed ID: 8056231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Importance of Monitoring the Postpartum Period in Moderate to Severe Crohn's Disease.
    Bennett A; Mamunes A; Kim M; Duley C; Garrett A; Annis K; Wagnon J; Dalal R; Scoville E; Beaulieu D; Schwartz D; Horst S
    Inflamm Bowel Dis; 2022 Mar; 28(3):409-414. PubMed ID: 33999196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bacteria-related Events and the Immunological Response of Onset and Relapse Adult Crohn's Disease Patients.
    Cantó E; Zamora C; Garcia-Planella E; Gordillo J; Ortiz MA; Perea L; Vidal S
    J Crohns Colitis; 2019 Jan; 13(1):92-99. PubMed ID: 30247652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crohn's Disease: Diagnosis and Management.
    Veauthier B; Hornecker JR
    Am Fam Physician; 2018 Dec; 98(11):661-669. PubMed ID: 30485038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of claims-based indicators used to identify flare-ups in inflammatory bowel disease.
    Burisch J; Zhang H; Choong CK; Nelson D; Naegeli A; Gibble T; Goetz I; Egeberg A
    Therap Adv Gastroenterol; 2021; 14():17562848211004841. PubMed ID: 33868458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physical Activity Levels and Social Cognitive Theory Correlates among Adults with Crohn's Disease: Preliminary Results from a Cross-Sectional Analysis.
    Neal WN; Pekmezi D; Motl RW
    Int J Environ Res Public Health; 2024 Apr; 21(4):. PubMed ID: 38673373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Wang Y; MacDonald JK; Hanauer S
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High altitude journeys and flights are associated with an increased risk of flares in inflammatory bowel disease patients.
    Vavricka SR; Rogler G; Maetzler S; Misselwitz B; Safroneeva E; Frei P; Manser CN; Biedermann L; Fried M; Higgins P; Wojtal KA; Schoepfer AM
    J Crohns Colitis; 2014 Mar; 8(3):191-9. PubMed ID: 23953239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Increase of resting energy expenditure during flare-ups in Crohn disease].
    Rigaud D; Cerf M; Angel Alberto L; Sobhani I; Carduner MJ; Mignon M
    Gastroenterol Clin Biol; 1993; 17(12):932-7. PubMed ID: 8125226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease.
    Lichtenstein GR; Hanauer SB; Kane SV; Present DH
    Inflamm Bowel Dis; 2004 Jul; 10 Suppl 2():S2-10. PubMed ID: 15475770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
    Feagan BG; Sandborn WJ; Danese S; Wolf DC; Liu WJ; Hua SY; Minton N; Olson A; D'Haens G
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):819-828. PubMed ID: 32553149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Competing with Crohn's disease: management issues in active patients.
    Ng VK; Millard WM
    Phys Sportsmed; 2005 Nov; 33(11):47-53. PubMed ID: 20086340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of Helicobacter pylori infection on the phenotype of Crohn's disease.
    Püspök A; Dejaco C; Oberhuber G; Waldhör T; Hirschl AM; Vogelsang H; Gasche C
    Am J Gastroenterol; 1999 Nov; 94(11):3239-44. PubMed ID: 10566722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crohn's disease, pregnancy, and birth weight.
    Moser MA; Okun NB; Mayes DC; Bailey RJ
    Am J Gastroenterol; 2000 Apr; 95(4):1021-6. PubMed ID: 10763954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Visceral Adiposity Independently Predicts Time to Flare in Inflammatory Bowel Disease but Body Mass Index Does Not.
    Sehgal P; Su S; Zech J; Nobel Y; Luk L; Economou I; Shen B; Lewis JD; Freedberg DE
    Inflamm Bowel Dis; 2024 Apr; 30(4):594-601. PubMed ID: 37307420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The microbiome of Crohn's disease aphthous ulcers.
    O'Brien CL; Kiely CJ; Pavli P
    Gut Pathog; 2018; 10():44. PubMed ID: 30337963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial.
    Prantera C; Cottone M; Pallone F; Annese V; Franzè A; Cerutti R; Bianchi Porro G
    Gastroenterology; 1999 Mar; 116(3):521-6. PubMed ID: 10029609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.